1. Home
  2. CAN vs NMRA Comparison

CAN vs NMRA Comparison

Compare CAN & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAN
  • NMRA
  • Stock Information
  • Founded
  • CAN 2013
  • NMRA 2019
  • Country
  • CAN Singapore
  • NMRA United States
  • Employees
  • CAN N/A
  • NMRA N/A
  • Industry
  • CAN Semiconductors
  • NMRA
  • Sector
  • CAN Technology
  • NMRA
  • Exchange
  • CAN Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • CAN 330.5M
  • NMRA 268.5M
  • IPO Year
  • CAN 2019
  • NMRA 2023
  • Fundamental
  • Price
  • CAN $0.78
  • NMRA $1.80
  • Analyst Decision
  • CAN Strong Buy
  • NMRA Buy
  • Analyst Count
  • CAN 6
  • NMRA 8
  • Target Price
  • CAN $2.50
  • NMRA $7.14
  • AVG Volume (30 Days)
  • CAN 34.8M
  • NMRA 721.6K
  • Earning Date
  • CAN 08-14-2025
  • NMRA 08-06-2025
  • Dividend Yield
  • CAN N/A
  • NMRA N/A
  • EPS Growth
  • CAN N/A
  • NMRA N/A
  • EPS
  • CAN N/A
  • NMRA N/A
  • Revenue
  • CAN $345,360,000.00
  • NMRA N/A
  • Revenue This Year
  • CAN $115.67
  • NMRA N/A
  • Revenue Next Year
  • CAN $63.75
  • NMRA N/A
  • P/E Ratio
  • CAN N/A
  • NMRA N/A
  • Revenue Growth
  • CAN 82.40
  • NMRA N/A
  • 52 Week Low
  • CAN $0.53
  • NMRA $0.61
  • 52 Week High
  • CAN $3.27
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • CAN 55.55
  • NMRA 59.49
  • Support Level
  • CAN $0.64
  • NMRA $1.56
  • Resistance Level
  • CAN $0.77
  • NMRA $1.80
  • Average True Range (ATR)
  • CAN 0.05
  • NMRA 0.10
  • MACD
  • CAN 0.01
  • NMRA 0.00
  • Stochastic Oscillator
  • CAN 78.14
  • NMRA 95.06

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: